ReviewJBMR plus2018
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy.
Review in JBMR plus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 88 citations in OpenAlex.
- Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2022Trial
- Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.The Journal of clinical endocrinology and metabolism · 2020Trial
- Bone-specific alkaline phosphatase as a marker of bone formation: Clinical and imaging correlates.World journal of experimental medicine · 2026Review
- Treatment Patterns in Hospitalized Hip Fracture Patients: An Interrupted Time-Series Analysis Around the New Fee for Secondary Fracture Prevention in Japan.Rheumatology and therapy · 2026Article
- Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties.Current osteoporosis reports · 2026Review
- Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide-induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Longitudinal osteoporosis therapy: treat-to-target and sequential strategies-a narrative review.Therapeutic advances in musculoskeletal disease · 2026Review
- Bone Optimization for Perioperative Spine Patients: A Multidisciplinary Approach at a Single Academic Center.Journal of clinical medicine · 2025Article
- Digital twin simulations with a micro-multiphysics agent-based model reveal key drivers of bone loss after denosumab discontinuation.Frontiers in bioengineering and biotechnology · 2025Article
- Distal Radius Fractures as a Call to Action: Reducing Subsequent Fragility Fracture Risk Through Early Osteoporosis Therapy.Geriatric orthopaedic surgery & rehabilitation · 2025Article
- Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Renal Function Is Associated with Changes in Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Denosumab: Data From a Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Recommendations for the optimal use of bone forming agents in osteoporosis.Aging clinical and experimental research · 2024Review
- The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II.Journal of menopausal medicine · 2024Review
- Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review.Biomedicines · 2024Review
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- 2,4'-Dihydroxybenzophenone Exerts Bone Formation and Antiosteoporotic Activity by Stimulating the β-Catenin Signaling Pathway.ACS pharmacology & translational science · 2024Article
- Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials.EClinicalMedicine · 2024Article
- The short-chain fatty acid receptors Gpr41/43 regulate bone mass by promoting adipogenic differentiation of mesenchymal stem cells.Frontiers in endocrinology · 2024Article
- Strontium ranelate enriched Ruminococcus albus in the gut microbiome of Sprague-Dawley rats with postmenopausal osteoporosis.BMC microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As osteoporosis therapy options have expanded, and clinical guidelines have begun to embrace the concept of limited treatment courses and "drug holidays," the choices that physicians must make when initiating, electing to continue, or switching therapies have become more complex. As a result, one of the fundamental issues that must be carefully considered is whether, when, and in what sequence anabolic therapies should be utilized. This review evaluates the current evidence supporting the optimal sequence for the use of anabolic and antiresorptive drugs and assesses the expanding number of clinical trials favoring the initial use of anabolic therapy followed by an antiresorptive agent. This review also explores the evidence suggesting that the effectiveness of anabolic medications are diminished when used in patients that have been previously treated with specific antiresorptive drugs for prolonged periods. Finally, the recent advances in designing combination antiresorptive/anabolic treatment approaches are detailed, with a focus on combined denosumab/teriparatide regimens, which appear to provide the most substantial and clinically relevant skeletal benefits to patients with established osteoporosis. © 2018 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.